Wagner 1993.
| Methods | Retrospective uncontrolled study | |
| Participants | 58 patients with advanced‐stage ovarian cancer after primary treatment with high preoperative CA‐125 levels (disease status at study entry not described) | |
| Interventions | Intravenous monoclonal antibody fragments (F(Ab)2‐fragments of MAb OC125 ‐ CA‐125) | |
| Outcomes | Survival Tumour responses Immune responses: humoral (Ab2), cellular |
|
| Notes | ||
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | High risk | Uncontrolled trial |
| Allocation concealment (selection bias) | High risk | Uncontrolled trial |
| Blinding of participants and personnel (performance bias) All outcomes | Unclear risk | Information insufficient to permit judgement of ‘low risk’ or ‘high risk’ |
| Blinding of outcome assessment (detection bias) All outcomes | Unclear risk | Information insufficient to permit judgement of ‘low risk’ or ‘high risk’ |
| Incomplete outcome data (attrition bias) All outcomes | Unclear risk | Information insufficient to permit judgement of ‘low risk’ or ‘high risk’ |
| Selective reporting (reporting bias) | Unclear risk | Information insufficient to permit judgement of ‘low risk’ or ‘high risk’ |
| Other bias | Unclear risk | Information insufficient to permit judgement of ‘low risk’ or ‘high risk’ |
Ab2: anti‐idiotype antibody. Ab3: anti‐anti‐idiotype antibody. CA‐125: cancer antigen‐125. CEA: carcinoembryonic antigen. EpCAM: epithelial cell adhesion molecule. ErbB2: human Epidermal growth factor Receptor 2. FBP: folate binding protein. GM‐CSF: granulocyte‐macrophage colony‐stimulating factor. GPC3: antigen glypican‐3. HAMA: human‐anti‐mouse antibody. HLA: human leucocyte antigen. hTERT: telomerase reverse transcriptase. KLH: keyhole limpet haemocyanin. MAb: monoclonal antibody. MAGE‐A1: melanoma‐associated antigen A1. MUC1: Mucin‐1. NED: no evidence of disease. OC: ovarian carcinoma. OWD: 1‐week delayed PADRE: DR‐restricted Th helper epitope. poly‐ICLC: polyinosinic‐polycytidylic acid complexed with poly‐L‐lysine and carboxymethylcellulose. SIM: simultaneous infusion. SLP: synthetic long peptide.